POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new POORLY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to tame aggressive thyroid cancer
Disease control OngoingThis study is testing whether two drugs, lenvatinib and pembrolizumab, work better together for people with advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. Lenvatinib aims to block tumor growth, while pembrolizumab helps the body's immune syste…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New drug combo targets tough thyroid cancers
Disease control OngoingThis study is testing whether combining an immunotherapy drug called PDR001 with other targeted cancer drugs is safe and effective for treating advanced thyroid cancer that no longer responds to standard radioactive iodine treatment. The trial includes 19 adults with specific typ…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New hope for fighting rare, Fast-Growing thyroid cancer
Disease control OngoingThis study is testing whether combining a drug that helps the immune system fight cancer (atezolizumab) with different chemotherapy drugs can help people with aggressive forms of thyroid cancer that have spread or cannot be removed by surgery. The goal is to see if this combinati…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo aims to Re-Sensitize tough thyroid cancers to standard treatment
Disease control OngoingThis study is testing if adding an oral drug called trametinib can make radioactive iodine treatment work again for people with advanced thyroid cancer that has spread or come back and no longer responds to iodine. The goal is to see if trametinib helps the cancer absorb more iod…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Scientists train Patients' own cells to fight advanced cancers
Disease control OngoingThis study is testing a personalized cell therapy called LN-145 for patients with advanced cancers that have stopped responding to standard treatments. Doctors collect a patient's own immune cells from their tumor, grow large numbers of them in a lab, and then infuse them back in…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug aims to shrink tough thyroid tumors before surgeons operate
Disease control OngoingThis study is testing whether a targeted pill called selpercatinib can shrink thyroid tumors before surgery. It is for people with advanced thyroid cancer that has a specific genetic change (RET alteration). The goal is to see if shrinking the tumor first makes surgery easier and…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New drug combo aims to tame tough thyroid cancers
Disease control OngoingThis study is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can help control advanced thyroid cancer that has stopped responding to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this three-drug a…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC